OraSure Technologies (NASDAQ:OSUR) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of OraSure Technologies (NASDAQ:OSUR) from a hold rating to a sell rating in a research report sent to investors on Sunday.

Separately, Weiss Ratings upgraded shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $3.00.

OraSure Technologies Trading Up 0.2%

Shares of OSUR stock opened at $4.17 on Friday. The firm has a market capitalization of $287.10 million, a PE ratio of -4.01 and a beta of 1.00. The firm has a fifty day simple moving average of $4.17 and a two-hundred day simple moving average of $3.40. OraSure Technologies has a 12 month low of $2.08 and a 12 month high of $4.58.

Insiders Place Their Bets

In other OraSure Technologies news, Director Steven Kyle Boyd acquired 25,000 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were acquired at an average price of $2.99 per share, with a total value of $74,750.00. Following the completion of the transaction, the director owned 113,462 shares in the company, valued at approximately $339,251.38. This trade represents a 28.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On OraSure Technologies

Several large investors have recently made changes to their positions in OSUR. Peapod Lane Capital LLC grew its position in OraSure Technologies by 51.1% during the fourth quarter. Peapod Lane Capital LLC now owns 1,018,470 shares of the medical instruments supplier’s stock valued at $2,465,000 after buying an additional 344,437 shares during the period. Tudor Investment Corp ET AL purchased a new stake in OraSure Technologies during the third quarter worth about $808,000. Yorkville Advisors Global LP bought a new stake in OraSure Technologies in the first quarter worth about $1,905,000. AQR Capital Management LLC raised its position in OraSure Technologies by 48.3% in the first quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock worth $3,511,000 after acquiring an additional 339,493 shares during the period. Finally, Archon Capital Management LLC purchased a new position in OraSure Technologies in the fourth quarter valued at about $1,388,000. 93.50% of the stock is owned by hedge funds and other institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.